Oncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research report released on Thursday morning. The firm issued a hold rating on the stock.

Separately, HC Wainwright decreased their price objective on Oncternal Therapeutics from $30.00 to $28.00 and set a buy rating on the stock in a report on Monday, April 15th.

Oncternal Therapeutics Stock Performance

ONCT stock opened at $8.29 on Thursday. The company has a market capitalization of $22.30 million, a price-to-earnings ratio of -0.61 and a beta of 1.26. Oncternal Therapeutics has a fifty-two week low of $5.57 and a fifty-two week high of $13.14. The stock has a fifty day moving average of $8.84 and a 200-day moving average of $8.24.

Oncternal Therapeutics (NASDAQ:ONCT) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($3.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.09) by ($0.02). Oncternal Therapeutics had a negative return on equity of 95.87% and a negative net margin of 5,029.17%. The company had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.17 million. During the same period last year, the company posted ($4.00) EPS. Equities analysts predict that Oncternal Therapeutics will post -10.67 EPS for the current year.

Insider Buying and Selling

In other Oncternal Therapeutics news, Director Robert James Wills acquired 3,086 shares of the business’s stock in a transaction dated Monday, April 8th. The shares were purchased at an average cost of $8.96 per share, for a total transaction of $27,650.56. Following the transaction, the director now owns 10,000 shares in the company, valued at $89,600. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have purchased a total of 10,714 shares of company stock worth $92,736 in the last ninety days. 8.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Oncternal Therapeutics

A hedge fund recently raised its stake in Oncternal Therapeutics stock. Richmond Brothers Inc. raised its stake in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) by 69.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 494,042 shares of the company’s stock after buying an additional 203,010 shares during the quarter. Oncternal Therapeutics comprises about 0.3% of Richmond Brothers Inc.’s investment portfolio, making the stock its 22nd biggest holding. Richmond Brothers Inc. owned about 0.84% of Oncternal Therapeutics worth $148,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 16.05% of the company’s stock.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.